These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34423657)

  • 41. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Judicious Use of Ozanimod for Ulcerative Colitis and Multiple Sclerosis.
    Jhon GF; Forster EM
    ACG Case Rep J; 2024 Apr; 11(4):e01332. PubMed ID: 38628167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.
    Choden T; Cohen NA; Rubin DT
    Gastroenterol Hepatol (N Y); 2022 May; 18(5):265-271. PubMed ID: 36397756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA; Selmaj KW; Steinman L; Comi G; Bar-Or A; Arnold DL; Hartung HP; Montalbán X; Havrdová EK; Sheffield JK; Minton N; Cheng CY; Silva D; Kappos L; Cohen JA
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
    Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
    Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
    Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK; Wang JJ
    Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.
    Cohen NA; Choi D; Choden T; Cleveland NK; Cohen RD; Rubin DT
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2407-2409.e2. PubMed ID: 35381385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone.
    Vuyyuru SK; Morrow SA; Jairath V
    ACG Case Rep J; 2023 Jan; 10(1):e00955. PubMed ID: 36699181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW; Cohen JA; Comi G; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Havrdova EK; Cree BAC; Minton N; Sheffield JK; Ding N; Kappos L
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
    Taylor Meadows KR; Steinberg MW; Clemons B; Stokes ME; Opiteck GJ; Peach R; Scott FL
    PLoS One; 2018; 13(4):e0193236. PubMed ID: 29608575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.